SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is trending after securing a significant licensing deal with Pfizer for its Matrix-M adjuvant, marking a key validation of its vaccine platform. This news is igniting widespread community discussion and strong bullish sentiment for a potential short squeeze, given the substantial short interest. Many investors view this partnership as a crucial step towards further collaborations and a re-evaluation of the company's long-term value.

TMC the metals co., Inc. is a deep-sea minerals exploration company focused on the collection and processing of polymetallic nodules found on the seafloor in international waters of the Clarion Clipperton Zone in the Pacific Ocean (CCZ). These nodules contain high grades of four metals (nickel, copper, cobalt, manganese) which can be used as (i) feedstock for battery cathode precursors (nickel, cobalt and manganese sulfates, or intermediate nickel-copper-cobalt matte) for electric vehicles (EV) and renewable energy storage markets, (ii) copper cathode for EV wiring, energy transmission and other applications and (iii) manganese silicate for manganese alloy production required for steel production. The company was founded in 2021 and is headquartered in Vancouver, Canada.

TMC the metals company Inc

TMC the metals company Inc. is experiencing significant investor attention following recent U.S. regulatory advancements, including modernized deep-sea mining permits and an upcoming Congressional hearing featuring its CEO. The community is highly optimistic, interpreting these moves as strong government alignment to expedite critical mineral recovery for national security, anticipating substantial upside for the company.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as CEO Ryan Cohen significantly increased his stake with a substantial open-market share purchase, a move echoed by another board member. This has sparked intense discussion among the community, with many viewing it as a strong bullish signal and potential catalyst for a major upward movement, while others remain cautious given prior market behavior.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is seeing significant activity as President Trump's announcement of a Greenland "framework" and the suspension of EU tariffs fueled a rapid market rebound. Traders are actively discussing the "TACO trade," where initial geopolitical uncertainty quickly reversed, leaving bears burned and reinforcing the "buy the dip" strategy amidst perceived market manipulation. This volatility underscores how headline-driven events continue to create dramatic swings in market sentiment.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio (IBRX) is experiencing significant market attention following recent Saudi FDA approval for its Anktiva lung cancer treatment and ongoing dialogue with the FDA for a bladder cancer resubmission. The community is intensely focused on the escalating cost to borrow and diminishing share availability, widely anticipating a massive short squeeze that could propel the stock higher. Many investors are actively "loading the boat," confident in the company's cancer immunotherapy advancements and viewing current market dynamics as a temporary battle against "trapped" short sellers.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is actively discussed amidst evolving geopolitical developments surrounding Greenland's rare earth mineral rights, particularly following recent statements from former President Trump and upcoming business updates. Investors are closely watching for definitive outcomes, with many anticipating a significant boost from any potential deal securing U.S. access to Greenland's vast critical metal deposits, despite notable short-term volatility and accusations of market manipulation.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed is trending following news that its subsidiary, Lucid Diagnostics, has secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, broadening access to precancer screening. This development, combined with the stock's low float, is fueling intense community discussion about a potential short squeeze and substantial upside, although some express concerns about possible dilution.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing a notable surge, primarily fueled by promising 5-year clinical data for its personalized cancer vaccine in collaboration with Merck and recent global regulatory submissions for its seasonal flu vaccine. The community is actively discussing the company's improved financial outlook and strategic shift towards its diverse mRNA pipeline beyond prior vaccine products. This reevaluation is amplified by a significant short interest, with many anticipating continued momentum in the broader biotech sector.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is experiencing an extraordinary rally, driven by analyst upgrades and surging demand for memory and data storage in the AI infrastructure sector, notably influenced by Nvidia's new chip requirements. This rapid ascent has ignited fierce debate within the community, with many celebrating its "unstoppable" momentum while an equally vocal segment warns of an unsustainable "bubble" and impending correction.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital (NUAI) is trending due to a significant partnership with Primary Digital Infrastructure for a massive AI data center campus in West Texas, coupled with a key acquisition. The community is actively discussing strong price action and anticipating an imminent announcement regarding a hyperscaler tenant, fueling speculation of continued upward momentum and a potential short squeeze within the burgeoning AI infrastructure sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Aptevo Therapeutics Shares Are Trading Lower By Around 38%? Here Are Other Stocks Moving In Friday's Mid-Day Session

<ul class="summary-bullets"><li>During the company’s annual meeting in July, shareholders authorized the board to finalize a reverse split within a 1-for-6 to 1-for-20 range.</li><li>The stock will begin trading on a split-adjusted basis on the Nasdaq Capital Market on December 30.</li><li>The company’s net loss for the third quarter widened to $7.5 million from $5.1 million during the year-ago period.</li></ul>Aptevo Therapeutics Inc. (APVO) stock slumped 45% to an all-time low on Friday after the company announced a 1-for-18 reverse stock split, effective after market hours on December 29.The reverse split will consolidate 18 outstanding shares into one, with split-adjusted trading set to begin on the Nasdaq Capital Market on December 30. The move will cut Aptevo’s issued and outstanding shares from about 18 million to roughly a million.Shareholders approved the proposal at the company’s annual meeting on July 24, authorizing the board to finalize a reverse split within a 1-for-6 to 1-for-20 range. The board set the final ratio on December 17.A reverse stock split is aimed at maintaining the stock’s compliance with Nasdaq’s listing requirements by meeting the $1 minimum bid price requirement.<h2 class="st-heading-2">Aptevo’s Q3 Highlights</h2>The company’s net loss for the third quarter (Q3) widened to $7.5 million, or $2.23 per share, from a loss of $5.1 million, or $357.86 per share, in the previous corresponding period.It raised $18.7 million during the quarter and an additional $4.1 million after quarter-end, extending its cash runway into the fourth quarter (Q4) of 2026. Aptevo said the runway would support key clinical milestones next year.Following those results, Aptevo introduced its trispecific antibody, APVO451, designed to counter immune suppression in solid tumors and built on the same binding domain as its lead candidate, Mipletamig, which has demonstrated a favorable safety profile.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/APVO">Aptevo Therapeutics</a> trended in the 'bearish' territory at the time of writing.<figure class="image"><img style="aspect-ratio:922/97;" src="https://news.stocktwits-cdn.com/APVO_png_7ab961f5fc.webp" alt="APVO.png" width="922" height="97"><figcaption>APVO's Sentiment Meter and Message Volumes at 10:45 a.m. ET on Dec. 26, 2025 | Source: Stocktwits</figcaption></figure>One user was hopeful of a buyout following the reverse split.<stembedurl>https://stocktwits.com/DonZulu/message/640151182</stembedurl>Another user said that the stock could have an attractive setup on Tuesday next week, with the 1-day moving average convergence divergence (MACD) a key indicator for potential entry.<stembedurl>https://stocktwits.com/GoImugene/message/640157497</stembedurl>Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mag-7-2025-review-on-charts/cLeU7wOREwN">As 2025 Bids Adieu, A Look At How Mag 7 Stocks Are Positioned On Charts</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Plug Power said it was impacted by the speed and development of hydrogen economy.

Aptevo Therapeutics Stock Slumps To All-Time Low On Reverse Split Approval

The move will cut Aptevo’s issued and outstanding shares from about 18 million to roughly a million.

Equity

What's Going On With Aptevo Therapeutics Stock Today?

Shares of Aptevo Therapeutics are trading lower Friday after the Seattle-based company announced a one-for-eighteen reverse stock split.read more...

Aptevo Therapeutics (APVO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Aptevo Therapeutics (APVO) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Aptevo Therapeutics (APVO) announced on Tuesday that a 100% remission rate was observed in a cohort of its Phase 1b/2 trial evaluating Mipletamig, in combination with Venetoclax and Azacitidine for newly diagnosed patients with acute myeloid leukemia (AML).The <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/mipletamig-delivers-100-remission-rate-cohort-3-rainier-trial">study</a> enrolled patients unfit for intensive chemotherapy. No dose-limiting toxicities or cytokine release syndrome were observed in the trial or among any frontline patients treated with Mipletamig to date, the company said.The 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy, the company said. It added that 40% of treated patients achieved minimal residual disease (MRD)-negative status, a critical marker of remission.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/APVO">APVO stock</a> rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels. Shares of the company traded 8% higher at the time of writing.<figure class="image"><img style="aspect-ratio:573/61;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_2_26_05_PM_png_6c3f4781c1.webp" alt="APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="573" height="61"><figcaption>APVO's Sentiment Meter and Message Volume as of 2:26 p.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed concerns about a potential dip in the share price.<stembedurl>https://stocktwits.com/WEL16/message/628866258</stembedurl>Another highlighted the drop in share price after the initial jump following the news.&nbsp;<stembedurl>https://stocktwits.com/Avior68/message/628866230</stembedurl>The company said that it is actively enrolling patients for the next cohort at the next dose levels and will present current findings at a medical conference in the last quarter.APVO stock is down by 98% this year.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-fda-alleges-novo-nordisk-video-on-weight-loss-drugs-featuring-oprah-winfrey-is-false-or-misleading/chwyFEyRdzF">US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aptevo Therapeutics Stock Rallies On 100% Remission Rate In Acute Myeloid Leukemia Trial Cohort

The company stated that the 100% remission rate achieved at the highest dose level of the trial demonstrated the drug’s potential to redefine the frontline treatment landscape for newly diagnosed AML patients who are unfit for intensive chemotherapy.

Shares of Aptevo Therapeutics Inc. (APVO) rocketed 41% on Thursday after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://aptevotherapeutics.gcs-web.com/news-releases/news-release-details/aptevo-therapeutics-21-million-registered-direct-offering-and">said</a> it is looking to raise about $2.1 million in a registered direct offering and warrants sale.The company said it has entered into definitive securities purchase agreements for the purchase and sale of 1.76 million shares of its common stock in a registered direct offering and warrants to purchase up to 3.5 million shares of common stock in a concurrent private placement at a combined purchase price of $1.19 per share and accompanying warrant.The warrants will have an exercise price of $1.19 per share and will expire five years from the initial exercise date.The offering is expected to close on or about April 4.The company will use the net proceeds from the offering for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.On Stocktwits, retail investor sentiment about Aptevo jumped from ‘extremely bearish’ to ‘extremely bullish’ territory (97/100), hitting a one-year high. At the same time, message volume touched ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:652/153;" src="https://news.stocktwits-cdn.com/Screenshot_2025_04_03_at_11_35_45_AM_png_96a7494386.webp" alt="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK" width="652" height="153"><figcaption>APVO's Sentiment Meter and Message Volume as of 11:35 a.m. ET on April 3, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user opined that the registered direct offering may be a “bailout” to institutions who were short.&nbsp;<stembedurl>https://stocktwits.com/leon_dedrick/message/610264441</stembedurl>Another user, however, expressed optimism about the share price rising to $3.<stembedurl>https://stocktwits.com/Bulltacos/message/610259261</stembedurl><a href="https://stocktwits.com/symbol/APVO">APVO shares</a> have lost over 55% this year and nearly all its value over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/trump-liberation-day-impact-steel-stocks-tumble-with-broader-market/chf7RL4RbeK">Trump’s Liberation Day Impact – Steel Stocks Tumble With Broader Market, UBS Flags Tariffs As 'Incremental Negative' For These Companies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Aptevo Stock Rises On $2.1M Registered Direct Offering, Warrant Sale: Retail  Sentiment Touches Year-High

The company said that net proceeds from the offering will be used for the continued clinical development of product candidates, as working capital, and for other general corporate purposes.

Aptevo Therapeutics Inc. shares surged nearly 50% early Thursday on promising leukemia trial results, before paring gains in volatile trading.&nbsp;The stock drew significant heavy interest on Stocktwits, reaching the top 15 trending symbols list, where sentiment turned ‘extremely bullish’ amid a sharp rise in message volume.<figure class="image"><img style="aspect-ratio:1314/320;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/APVO_sentiment_and_message_volume_on_Dec_12_f6c2ca53dd.png" alt="APVO sentiment and message volume on Dec 12.png" width="1314" height="320"><figcaption>APVO sentiment and message volume on Dec 12 as of 11:45 am ET | source: Stocktwits</figcaption></figure>The company announced that all patients with acute myeloid leukemia (AML) treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.&nbsp;This includes two patients who experienced complete remission with 100% cancer cell elimination.&nbsp;The trial is exploring mipletamig as frontline therapy in combination with venetoclax and azacitidine, the current standard of care for AML.Retail traders speculated heavily on the stock’s movements, attributing volatility to its small public float of around 500,000 shares.&nbsp;Optimistic users expressed confidence in the company’s long-term potential, with one noting that they had bought 1,000 shares of Aptevo.Aptevo’s oncology pipeline targets aggressive forms of cancer. Other highlights include:• ALG.APV-527: Currently in Phase 1 for 5T4-expressing solid tumors like breast, colon, and non-small cell lung cancers. Preliminary data presented at leading oncology conferences has been positive.• Other preclinical candidates, including APVO711 (immune checkpoint blockade and activator) and APVO603 (dual co-stimulatory solid tumor targeting), are designed for precision cancer treatments.Aptevo stock remains down over 96% year-to-date, reflecting other ongoing challenges. Its current market cap is just over $5 million.Still, retail investors remain cautiously optimistic for now as the company builds on promising clinical data while addressing broader market pressures.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely Bullish

The company announced that all patients with acute myeloid leukemia treated with its lead candidate, mipletamig, achieved remission within 30 days in a Phase 1b trial.

Aptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which engages on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527, and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded in February 2016 and is headquartered in Seattle, WA.

Aptevo Therapeutics Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

APVO
Aptevo Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest APVO News

APVOAptevo Therapeutics Inc